investor presentation - immunoprecise antibodies ltd · 2020-02-17 · investor presentation tsxv :...

INVESTOR PRESENTATION TSXV : IPA – April 2017 OTC : IPATF

© ImmunoPrecise. All rights reserved

The Solution of Choice for Engineering Custom-Designed, Precision Antibodies

CEO, FIT Biotech and Chief Investment Officer

for a multibillion-dollar investment fund.

- and -

Chairman of the Board – ImmunoPrecise

There is a revolution taking place in therapeutics

& diagnostics, and ImmunoPrecise is ideally

situated to benefit from it.

” DR. JAMES KUO, M.D.

www.ImmunoPrecise.com Confidential | 2 | TSXV:IPA | OTC:IPATF

www.ImmunoPrecise.com

ENGINEER

OF

ANTIBODIES

Confidential | 3 | TSXV:IPA | OTC:IPATF

WHAT IS AN ANTIBODY?

ANTIBODIES ARE LARGE Y-

SHAPED PROTEINS.

Antigens Antigen binding site

Antibodies always pair with an

antigen (protein).

They identify and neutralize

foreign objects like bacteria and

viruses (antigens).


HOW ARE ANTIBODIES USED?

Drug-Diagnostic Combination

Research

Diagnostics

Therapeutics


Source: (Antibodies Market: Launch of Innovative Drugs and Easy Availability of Biosimilar is Expected to Boost the Demand: Global Industry Analysis and Opportunity Assessment 2016 - 2026

$105 B

$341 B

2016 2026

M A R K E T G R O W T H : A N T I B O D Y T H E R A P E U T I C S

CAGR=12.5%

H U M I R A ® (adalimumab)

$12 B in 2015

Largest selling Rx Drug

Genentech Biotechnology company

AVA S T I N ® (bevicizumab) $7.3 B in 2015

Most successful cancer drug of all time

MoAbs 54%

All others

46%

Source: 2015 Antibody Market

Report,Biocompare

DRUGS

IN

DEVELOPMENT


MACRO TREND MONOCLONAL ANTIBODIES (MoAbs) have emerged as a major source of blockbuster drugs


Source: (Antibodies Market: Launch of Innovative Drugs and Easy Availability of Biosimilar is Expected to Boost the Demand: Global Industry Analysis and Opportunity Assessment 2016 - 2026

$105 B

$341 B

2016 2026

M A R K E T G R O W T H : A N T I B O D Y T H E R A P E U T I C S

CAGR=12.5%


MACRO TREND

$105 B

$341 B

2016 2026

MARKET GROWTH: ANTIBODY THERAPEUTICS

Source: Antibodies Market: Launch of Innovative Drugs and Easy Availability of Biosimilar is Expected to Boost the Demand: Global Industry Analysis and

Opportunity Assessment 2016 - 2026

CAGR of 12.5%

▸ Contract drug manufacturer

▸ $2.0B IPO ($8.0B valuation)

▸ IPO valuation at 100x Revenue



1 4 6 8 10 2 3 7 5 9

(RHEUMATIC ARTHRITIS, ABBVID)

HUMIRA

(HEPATITIS C. GILEAD) HARVONI

(RHEUMATIC ARTHRITIS, AMGEN)

ENBREL

(RHEUMATIC ARTHRITIS, CROHNS, JOHNSON &

JOHNSON)

REMICADE

(ONCOLOGY, ROCHE)

MABTHERA, RITUXAN

(DIABETES, SANOFI) LANTUS

(ONCOLOGY, ROCHE) AVASTIN

(ONCOLOGY, ROCHE) HERCEPTIN

(ONCOLOY,CELGENE) REVLIMID

(HEPATITIS C, GILEAD) SOVALDI

BIOLOGICAL SMALL MOLECULE

2015 – TOP DRUGS BY GLOBAL SALES


Source: 2016-11-28 Mentlife seminar, Pharmaceutical Drug Development; An Overall Perspective (Page 11)

AB ENGINEERING FUNCTIONAL STUDIES PRODUCTION CELL LINE

DRUG DISCOVERY

PRECLINICAL DEVELOPMENT

PHASE 1 / 2 / 3

MARKET


$2.6 Average Drug Development Cost

USD BILLION

ANTIBODY THERAPEUTICS HUMANIZING ANTIBODIES - a key step in the development of successful therapeutics


Source: Tufts Center for the Study of Drug Development at Tufts University, published in May 2016 Issue of the Journal of Health Economics

Higher

Quality

Better

Replication

Faster & Cost

Effective


COMPETITIVE ADVANTAGES

IPA proprietary methodology

for developing antibodies

A recognized high-quality developer of some of the most difficult and technical antibody targets

Freezing, rescuing and sub

clone master cell banks

The DNA expression of the

engineered moAb


ANTIBODY CONTRACT

MANUFACTURING Highly scalable. Optimize efficiency.

Expand capacity. Commercial

structure

CRYOSTORAGE High margin.

At capacity and scaling

up. Targeting new areas.

CORP DEVELOPMENT

STRATEGIC GROWTH Consolidation through M&A.

Partnership Licensing.


CHIMERIC AND

HUMANIZED mABS High margin barriers to entry.

GROWTH STRATEGY

AB ENGINEERING FUNCTIONAL STUDIES PRODUCTION CELL

LINE

DRUG DISCOVERY

PRECLINICAL DEVELOPMENT

PHASE 1 / 2 / 3

MARKET



North America Vertical Integration Strategy

GLOBAL EXPANSION POTENTIAL


Strong Global Biotechnology Hubs and Clusters

Austin

San Diego

San Francisco

Los Angeles

Seattle Toronto Montreal Minneapolis/St. Paul

Boston New York/New Jersey

Philadelphia

Baltimore/Washington DC

Research Triangle NC

Belo Horizonte / Rio de Janeiro

Sao Paulo

Cape Town

Israel

Glasgow/Edinburgh Manchester/Liverpool

Dublin London

Cambridge/ SE England

BioAlps

Paris

Sophia-Antipolis

Brussels

Helsinki Stockholm/Uppsala

Biovalley BioTech Munich

Medicon Valley / BioCon Valley

DuBiotech

Mumbai

Bangalore

Hyderabad

Singapore

Hong Kong Hsinchu

Taipei

Kansai Tokyo

Hokkaido Beijing

Daejeon

Brisbane Sydney

Melbourne

Dunedin

International Partnership Strategy

R O B E R T B E E C R O F T Founder, Chief Technical Officer, Director

Mr. Beecroft is the president, former CEO and founder of IPA. He has over 25 years experience in the development of innovative and proprietary

methods for the production of monoclonal and polyclonal antibodies and peptides. Mr. Beecroft has a BSc in microbiology from University of

Victoria, and has been involved in over 15 research projects over the course of the last 25 years and been an instructor for graduate students at

the University of Victoria on the use and production of monoclonal antibodies.

T H O M A S D ’ O R A Z I O (MBA) Chief Executive Officer, Director

Mr. D'Orazio has served as chief executive officer of IPA since Aug. 28, 2016. Mr. D'Orazio is an experienced life science executive with over 20

years of experience developing and implementing strategic growth plans for notable industry companies such as Pfizer, Immunex, Merck and

QLT. Mr. D'Orazio has a BSc in organic chemistry from Loyola University of Chicago and an MBA from Vanderbilt University.

D E A N N A D R Y H U R S T Chief Scientific Officer

Dr. Dryhurst has been with ImmunoPrecise since 2010. She received an NSERC Industrial Research and Development Postdoctoral Fellowship to

work on a platform for rabbit monoclonal antibody development at ImmunoPrecise Antibodies. Rabbit monoclonal antibodies are now a key part of

what ImmunoPrecise provides to its clients. She is currently in charge of R&D at ImmunoPrecise where she is responsible for prioritization of

research projects, alignment with corporate strategy and developing new product introductions. She received her BSc in Biology, and her Ph.D. in

Biochemistry and Molecular Biology from the University of Victoria.

D A V I D O R T O N Chief Operating Officer

Mr. Orton is a business leader with a strong operational and process focus augmented with a sales and marketing skillset. Tenures include

executive level positions with Clean Energy Fuels Armtec, Bell Canada’s satellite communications group and Rogers Communications. In

previous roles he was responsible for global sales, marketing, application engineering, and product solutions teams with staff in 12 countries and

annual sales in excess of $80M. He has also had full P&L responsibility for a $35M business unit including 3 facilities and 100 employees with

direct reports including Operations, Engineering, Sales & Marketing, Customer Service, Product Management and Business Analysis.

L A U R E N S M I T H Vice President of Global Sales & Marketing

Ms. Smith is senior sales executive with over 20 years of success within the medical device, pharmacy services and pharmaceutical industries.

Tenures include senior sales leadership positions with Delfi Medical Technology, Acelity Corporation, Paragon Pharmacies, VSM MedTech, and

Eli Lilly. In previous positions she has driven impressive sales growth, managed all aspects of marketing and selling medical, and has built,

managed and supported highly successful inside and field sales teams consisting of both agents and direct account managers.


MANAGEMENT TEAM & BOARD


T E R I O T T O Head Of Laboratory Services

Ms. Otto joined ImmunoPrecise in 1997 as a co-op student and continued as a FT employee upon graduation in 2000. She began as a technician

and animal care manager. She has been a key part of developing ImmunoPrecise’s successful laboratory operations and antibody engineering

capabilities, particularly in the area of mouse hybridomas. Ms. Otto holds a BS (with distinction) from University of Victoria in Microbiology and

Associate Degrees in Psychology, Bio Chemistry, and Applied Chemistry from Camosum College in Victoria, BC.

K E V I N W O N G Vice President Of Corporate Services

Dr. Wong has served President of ImmunoPrecise and VP of Corporate Services since joining the company in 2013. Dr. Wong managed the

laboratory operations for Protox Therapeutics for nine years prior to joining ImmunoPrecise. Dr. Wong spent six years at Cambridge University as

a Research Associate in both the Departments of Biochemistry and Pathology, as well as two years as a Research Associate at University of

Ottawa Department of Cellular and Molecular Medicine. Dr. Wong graduated from University of Victoria with a Ph.D. in Biochemistry. Dr. Wong

has been published in more than a dozen peer-reviewed articles in journals of biological sciences.


MANAGEMENT TEAM & BOARD


D R . J A M E S K U O Chairman

Dr. Kuo, MD, MBA, is currently the chief executive officer of the Finnish biotech company FIT biotech ltd. Dr. Kuo is an experienced biotech

industry executive and investor who brings a wealth of business and management experience to the company. During his impressive career, he

has held executive positions in private and listed biotech companies in the united states. His most recent assignments have been as a CEO with

Biomicro Systems Inc., CEO of Synthetic Biologics Inc. (NYSE:SYN), CEO of Discovery Laboratories Inc. (NASDAQ:DSCO), and previously

worked as associate director in corporate licensing and development at Pfizer Inc. A physician by training, Dr. Kuo received his MBA at the

Wharton School of Business at the University of Pennsylvania. In addition, he holds a BA in molecular biology.

G U Y C H A M P A G N E Director

Mr. Champagne is an accomplished businessman and entrepreneur who formerly served as managing partner of BDC Consulting between 2006

and 2013, retiring in December, 2013. Mr. Champagne maintained designation as a certified management consultant (Canadian Association of

Certified Management Consultants) until 2016. He pursued education, including the Canadian Securities Course, the Canadian Institute of

Chartered Business Valuators training program for the chartered business valuator designation, and he has an honours mathematics degree

from McGill University. Mr. Champagne sits in advisory and board positions for a number of private and public entities.

G R E G S M I T H (MBA, CFA) Director

Mr. Smith is a seasoned capital markets veteran who held senior positions in investment banking before recently transitioning to private equity

with the acquisition of one of the largest HVAC companies in Western Canada. Mr. Smith also held the position of portfolio manager for Phillips,

Hagar & North, and executive director, Canadian securitization group, CIBC World Markets, in Toronto for close to 10 years. Mr. Smith, currently

serves as president and director of Broadway Refrigeration & Air Conditioning Co. Ltd. and Omega Mechanical Ltd. Mr. Smith earned an MBA

from Dalhousie University, is a Chartered Financial Analyst, and has served in advisory positions to multiple private and public ventures. He is

additionally serving as chairman of Lite Access Technologies.


PRINCIPAL SCIENTISTS D E A N N A D R Y H U R S T Chief Scientific Officer

Dr. Dryhurst has been with ImmunoPrecise since 2010. She received an NSERC Industrial Research and Development Postdoctoral

Fellowship to work on a platform for rabbit monoclonal antibody development at ImmunoPrecise Antibodies. Rabbit monoclonal

antibodies are now a key part of what ImmunoPrecise provides to its clients. She is currently in charge of R&D at ImmunoPrecise

where she is responsible for prioritization of research projects, alignment with corporate strategy and developing new product

introductions. She received her BSc in Biology, and her Ph.D. in Biochemistry and Molecular Biology from the University of Victoria.

A N D R A L I , P H D . Director Of Research & Development

Andra Li has spent the past 6 years at IPA refining the rabbit monoclonal antibody technology platform and developing

ImmunoProtect as part of their new service offerings. In addition to her role as Director, Dr. Li manages all operations of IPA’s

molecular unit. Dr. Li holds a BSc and a PhD in Biochemistry from University of Victoria. During her graduate studies, she examined

the role of histone variants in double stranded DNA repair. Dr. Li was awarded an NSERC Industrial Research and Development

Postdoctoral Fellowship to generate single chain antibodies from rabbit monoclonal antibodies at ImmunoPrecise.

D A V I D K R O E G E R , P H D . Senior Scientist

David Kroeger joined the IPA team in 2017 bringing with him a broad skillset in immunology, immuno-oncology, and antibody

technology. He earned his PhD in immunology at the University of Saskatchewan in 2012 where he studied cellular interactions

between B cells and T cells and their immunological outcomes. Dr. Kroeger then pursued postdoctoral training at the BC Cancer

Agency. During his time, he studied the immune response to human cancer and made discoveries regarding the role of B cells in

antitumor immunity. In addition to basic research, Dr. Kroeger made translational contributions including developing methods for

cloning fully human antibodies from single tumor infiltrating B cells.

Cryostorage business segment upside Operational efficiency gains will improve margins and allow scalability

Working Capital (as of January 31, 2017)

TSX Venture Exchange : IPA OTC : IPATF

Shares Outstanding

37.76 M

Fully Diluted

41.22 M

Insider Ownership

~40%

Convertible Note 0.65 M shares & 0.65 M warrants;


$ ~3.4 M

CAPITAL STRUCTURE

Warrants 0.5 M - Options 1.7 M


Strong reputation for high-quality, efficient antibody customization and production 1

2 Solid core business poised to grow:

Cryostorage business segment upside

Operational efficiency gains will improve margins and allow scalability

Aggressive business development strategy seeking log-scale gains in revenue and profit growth 3

Strong reputation for high-quality, efficient antibody customization and production.

Aggressive growth strategy seeking large-scale gains in revenue and profit growth

Solid core business poised to grow: - Cryostorage business segment

upside - Operational efficiency gains will

improve margins and allow scalability


IMMUNOPRECISE SUMMARY


[email protected] ImmunoPrecise Antibodies

4464 Markham Street, #3204 Victoria,

BC V8Z 7X8 Canada

www.immunoprecise.com

TSXV:IPA

OTC:IPATF


This presentation includes forward-looking statements and assumptions concerning our business, its operations and its financial performance and condition approved by management on the date of this presentation. These forward-looking statements and assumptions include, but are not limited to, statements with respect to our objectives and strategies to achieve those objectives, statements with respect to our beliefs, plans, expectations, anticipations, estimates or intentions, including guidance and forecasts relating to revenue, adjusted operating profit, PP&E expenditures, free cash flow, expected growth in customers we serve, the cost of acquiring customers and the development of new services and all other statements that are not historical facts. Such forward-looking statements are based on current objectives, strategies, expectations and assumptions, most of which are confidential and proprietary, that we believe to be reasonable at the time including, but not limited to, general economic and industry growth rates, currency exchange rates, product pricing levels and competitive intensity, subscriber growth and usage rates, changes in government regulation, technology deployment, the timing of new product launches, content and equipment costs, the integration of acquisitions, and industry

structure and stability. Except as otherwise indicated, this presentation and our forward-looking statements do not reflect the potential impact of any non-recurring or other special items or of any dispositions, monetizations, mergers, acquisitions, other business combinations or other transactions that may be considered or announced or may occur after the date of the financial information contained herein. We caution that all forward-looking information, including any statement regarding our current intentions, is inherently subject to change and uncertainty and that actual results may differ materially from the assumptions, estimates or expectations reflected in the forward-looking information. A number of factors could cause actual results to differ materially from those in the forward-looking statements or could cause our current objectives and strategies to change, including but not limited to economic conditions, technological change, the integration of acquisitions, unanticipated changes in supplies or equipment costs, changing conditions in the Regulatory environment, life sciences research industry, regulatory changes, litigation and tax matters, the level of competitive intensity and the emergence of new opportunities, many of which are beyond our control and current expectation or knowledge.

Therefore, should one or more of these risks materialize, should our objectives or strategies change, or should any other factors underlying the forward-looking statements prove incorrect, actual results and our plans may vary significantly from what we currently foresee. Accordingly, we warn investors to exercise caution when considering any such forward-looking information herein and that it would be unreasonable to rely on such statements as creating any legal rights regarding our future results or plans. We are under no obligation (and we expressly disclaim any such obligation) to update or alter any forward-looking statements or assumptions whether as a result of new information, future events or otherwise, except as required by law. Before making any investment decisions and for a more detailed discussion of the risks, uncertainties, material factors and assumptions associated with our business that were applied in drawing conclusions or making a forecasts set out in such forward-looking information, see the MD&A sections of our annual and quarterly filings regarding forward-looking statements, risks and assumptions. Our annual and quarterly reports can be found at www.Immunoprecise.com/filings, www.sedar.com


FORWARD LOOKING STATEMENTS


http://www.immunoprecise.com/filings





http://www.sedar.com/





investor presentation - immunoprecise antibodies ltd · 2020-02-17 · investor presentation tsxv :...

Documents